Article -> Article Details
| Title | Heart Failure Drugs Market Business Growth, Key Players and Future Scenario |
|---|---|
| Category | Fitness Health --> Health Insurance |
| Meta Keywords | Heart Failure Drugs Market |
| Owner | vinit |
| Description | |
| Market Highlights Global Heart
Failure Drugs Market is estimated to be valued at USD
13,069.75 Million by 2025 and is expected to register a CAGR
of 17.79% during the forecast period. Heart failure is a chronic condition in which the heart
muscle is unable to pump enough blood to the body’s need for blood and oxygen.
This results in fatigue and shortness of breath and sometimes results in a
cough. Factors such as rising cases of cardiovascular disorders, increasing
geriatric population, and the constantly changing lifestyle habits (such as
unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and
lack of physical activity) which make individuals more susceptible to
arrhythmia and heart failure are driving the market growth. Additionally,
a strong pipeline and product approvals are also driving the market growth.
However, serious side-effects hamper the growth of the market. Segment Analysis Global Heart Failure Drugs Market has been segmented on the
basis of Type, and End User. The market, based on type, has been segmented into
Beta-Blockers, ACE Inhibitors, Angiotensin-Receptor Neprilysin Inhibitors
(ARNI), Angiotensin Receptor Blockers (ARBs), Diuretic, and others. The global
heart failure drugs market, by end-user, has been categorized as hospitals,
specialty centers, and others. Regional Analysis Europe would follow the Americas in terms of value during
the forecast period owing to the presence of favorable government initiatives
and laws, and target population base, and the rising prevalence of
lifestyle-associated conditions. For instance, according to the European
Heart Journal, overall CVD is estimated to cost the EU economy EUR 210 billion
a year, and CVD accounted for over 126 million hospital bed days in the EU,
representing 277 hospital bed days per 1000 population. Asia-Pacific is expected to exhibit the fastest market
growth from 2019 to 2025 owing to the increasing per capita health spending,
growing older population base, developing the healthcare sector in China,
India, and Australia, a defined regulatory framework enabling accelerated
product approvals, and diagnostic process at comparatively lower prices. The Middle East and Africa are expected to represent a
modest market growth from 2019 to 2025. The Middle East would hold a
substantial market share over the assessment period due to increasing obesity
issues, rising initiatives by governments to improve patient care, and
favorable reimbursement policies Key Players Market Research Future (MRFR) recognizes Amgen Inc. (US), AstraZeneca (UK), Novartis
AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson
& Johnson Services, Inc. (UK), Bristol-Myers Squibb Company (US), Merck
Sharp & Dohme Corp. (US), Pfizer, Inc. (US), and Gilead
Sciences, Inc. (California) as the Key Players in the Global
Heart Failure Drugs Market. Key Findings of the Study
| |